Clinical trials: Metastatic Castration-Resistant Prostate Cancer Patients
Metastatic Prostate Cancer
Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer
This is a randomized, double blind, multi-institutional phase II therapeutic study of Indoximod or placebo after the completion of standard of care sipuleucel-T (Provenge®) in men with asymptomatic or minimally symptomatic…
- Trial name
- NCT01560923
- Testing
- Indoximod, Sipuleucel-T
- Where
- 4 sites in United States
- Volunteers
- 47 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Metastatic Castration-resistant Prostate Cancer
Study of Enzalutamide in Patients With Castration-resistant Prostate Cancer
This research study is evaluating a drug called enzalutamide in metastatic castration resistant prostate cancer. Enzalutamide is already FDA approved for metastatic castration resistant prostate cancer after treatment with…
- Trial name
- NCT01942837
- Testing
- Enzalutamide
- Where
- 5 sites in United States
- Volunteers
- 67 people
- Sponsor
- Dana-Farber Cancer Institute
Metastatic Breast Cancer, Advanced Breast Cancer
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
This is a study using sunitinib for patients ending treatment on a previous sunitinib malate protocol to continue to receive sunitinib.
- Conditions
- Metastatic Breast Cancer, Advanced Breast Cancer, Metastatic Castration Resistant Prostate Cancer, Metastatic Renal Cell Cancer
- Trial name
- NCT00428220
- Testing
- sunitinib
- Where
- 113 sites in United States, Argentina and 15 more
- Volunteers
- 223 people
- Sponsor
- Pfizer
Prostate Cancer
Study Comparing Orteronel Plus Prednisone in Participants With Metastatic Castration-Resistant Prostate Cancer.
This is a randomized, double-blind, multicenter, phase 3 study evaluating orteronel plus prednisone compared with placebo plus prednisone in men with metastatic, castration-resistant prostate cancer (mCRPC) that has progressed…
- Trial name
- NCT01193257
- Testing
- Orteronel, Prednisone
- Where
- 78 sites in United States, Australia and 12 more
- Volunteers
- 1,099 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Prostate Cancer Metastatic
Cabazitaxel Versus the Switch to Alternative AR Targeted Therapy Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Primary Resistant Patients to Abiraterone or Enzalutamide
Primary Objective: To demonstrate the superiority in term of radiographic Progression-Free Survival (rPFS) of cabazitaxel at at 25 milligram per meter square (mg/m^2) plus prednisone (Arm A) versus either enzalutamide at 160…
- Trial name
- PRIMCAB (NCT02379390)
- Testing
- Cabazitaxel XRP6258, Ezalutamide, Abiraterone acetate
- Where
- 24 sites in United States, Canada
- Volunteers
- 8 people
- Sponsor
- Sanofi
Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer
Linsitinib in Treating Patients With Asymptomatic or Mildly Symptomatic Metastatic Prostate Cancer
This phase II trial studies how well linsitinib works in treating patients with asymptomatic or mild symptomatic metastatic prostate cancer.
- Conditions
- Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- NCT01533246
- Testing
- linsitinib, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Study of Abiraterone Acetate and Prednisone in Combination With Cabazitaxel in Patients With Prostate Cancer
Patients are being asked to take place in this research study because they have advanced prostate cancer that has gotten worse after other treatments.
- Trial name
- NCT01845792
- Testing
- Cabazitaxel with Abiraterone Acetate, Cabazitaxel
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Colorado, Denver
Prostate Cancer Metastatic
Trial of Cabozantinib (XL184) in Castrate-Resistant Prostate Cancer Metastatic to Bone
The purpose of this study is to look at the effects of cabozantinib on castrate-resistant prostate cancer metastatic (cancer that has spread to other parts of the body) to the bone and to learn about any side effects caused by…
- Trial name
- NCT01428219
- Testing
- Cabozantinib
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Michigan Rogel Cancer Center
Prostate Cancer
Study of Lanreotide in Non Metastatic Castration-resistant Prostate Cancer Patients
The aim of the study is to compare in an exploratory fashion the efficacy on progression-free survival of lanreotide in addition to non steroidal anti androgens and LHRH-a in non metastatic castrate resistant prostate cancer…
- Trial name
- POSEIDON (NCT01313273)
- Testing
- Lanreotide, non steroidal anti androgens and LHRH-a, Non steroidal anti androgens and LHRH-a
- Where
- Italy
- Volunteers
- 3 people
- Sponsor
- Ipsen
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma
PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer
This phase I trial studies side effects and best dose of PSCA-chimeric antigen receptor (CAR) T cells in treating patients with prostate stem cell antigen positive (PSCA+) castration resistant prostate cancer that has spread to…
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
- Trial name
- NCT03873805
- Testing
- Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- City of Hope Medical Center
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma
ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer
This phase II trial studies the side effects of ESK981 and nivolumab and to see how well they work for the treatment of castration resistant prostate cancer that has spread to other places in the body (metastatic).
- Conditions
- Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Carcinoma Metastatic in the Bone
- Trial name
- NCT04159896
- Testing
- Pan-VEGFR/TIE2 Tyrosine Kinase Inhibitor CEP-11981, Nivolumab
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma
68Ga-PSMA-11 PET/CT Screening Prior to 177Lu-PSMA-617 Therapy for Patients With Metastatic Castrate Resistant Prostate Cancer
This phase III study provides access to 68Ga-PSMA-11 positron emission tomography (PET)/computed tomography (CT) imaging for patients with castrate-resistant prostate cancer that has spread to other places in the body…
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
- Trial name
- NCT05547386
- Testing
- Computed Tomography, Gallium Ga 68 Gozetotide, Positron Emission Tomography
- Where
- United States
- Volunteers
- 163 people
- Sponsor
- Mayo Clinic
Prostate Cancer, Castration Resistant Prostate Cancer
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
This study will evaluate the effect of cabozantinib compared to prednisone on overall survival in men with previously treated metastatic castration-resistant prostate cancer with bone-dominant disease who have experienced disease…
- Conditions
- Prostate Cancer, Castration Resistant Prostate Cancer, Pain, Prostatic Neoplasms
- Trial name
- COMET-1 (NCT01605227)
- Testing
- cabozantinib, prednisone
- Where
- 264 sites in United States, Australia and 12 more
- Volunteers
- 1,028 people
- Sponsor
- Exelixis
Prostate Cancer
Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer
Multicenter open label, uncontrolled study that enrolled men with metastatic castrate resistant prostate cancer previously treated with sipuleucel-T in the androgen dependent setting in the Dendreon P-11 study.
- Trial name
- mCRPC (NCT01338012)
- Testing
- sipuleucel-T
- Where
- 4 sites in United States
- Volunteers
- 8 people
- Sponsor
- Dendreon
Prostate Cancer
Docetaxel and Hydroxychloroquine in Treating Patients With Metastatic Prostate Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00786682
- Testing
- docetaxel, hydroxychloroquine
- Where
- 7 sites in United States
- Volunteers
- 11 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Prostate Cancer
Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate Cancer
The purpose of this study is to find out the effects of giving durvalumab alone or in combination with tremelimumab on this type of cancer.
- Trial name
- NCT02788773
- Testing
- Durvalumab, Tremelimumab
- Where
- 11 sites in Canada
- Volunteers
- 52 people
- Sponsor
- Canadian Cancer Trials Group
Prostate Cancer
Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer
This is a phase 3 study to compare the clinical benefit of abiraterone acetate plus prednisone with placebo plus prednisone in asymptomatic or mildly symptomatic patients with metastatic castration-resistant prostate cancer…
- Trial name
- NCT00887198
- Testing
- Abiraterone acetate, Prednisone
- Where
- 134 sites in United States, Australia and 9 more
- Volunteers
- 1,088 people
- Sponsor
- Janssen Research & Development, LLC
Prostate Cancer
Abiraterone With Different Steroid Regimens for Side Effect Related to Mineralcorticoid Excess Prevention in Prostate Cancer Prior to Chemotherapy
The purpose of the study is to determine the safety and clinical benefit of the combinations of abiraterone acetate and prednisone or abiraterone and dexamethasone in prostate cancer patients.
- Trial name
- NCT01867710
- Testing
- Abiraterone Acetate, Prednisone 5 mg twice daily, Prednisone 5 mg once daily
- Where
- 17 sites in Belgium, Germany and 2 more
- Volunteers
- 164 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma
Pembro and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer
This phase II trial studies how well pembrolizumab and HER2Bi-armed activated T cells work in treating patients with castration resistant prostate cancer that has spread to other places in the body.
- Conditions
- Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Prostate Carcinoma Metastatic in the Bone, PSA Progression
- Trial name
- NCT03406858
- Testing
- HER2Bi-Armed Activated T Cells, Laboratory Biomarker Analysis, Pembrolizumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma
M6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
This phase II trial studies how well berzosertib (M6620) and carboplatin with or without docetaxel works in treating patients with castration-resistant prostate cancer that has spread to other places in the body (metastatic).
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8
- Trial name
- NCT03517969
- Testing
- Berzosertib, Carboplatin, Docetaxel
- Where
- 23 sites in United States
- Volunteers
- 73 people
- Sponsor
- National Cancer Institute (NCI)